Ezogabine: A New Angle on Potassium Gates
Open Access
- 1 May 2011
- journal article
- Published by SAGE Publications in Epilepsy Currents
- Vol. 11 (3) , 75-78
- https://doi.org/10.5698/1535-7511-11.3.75
Abstract
Ezogabine is a new drug for adjunctive therapy of partial-onset seizures with a novel mechanism of action. As a potassium-channel facilitator, it promotes membrane repolarization and thus opposes rapid repetitive discharges. Side effects are typical for antiepileptic drugs and the safety profile is good. Occasional instances of urinary difficulty may require surveillance.Keywords
This publication has 25 references indexed in Scilit:
- Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel InteractionsJournal of Biological Chemistry, 2010
- NeuralKCNQ(Kv7) channelsBritish Journal of Pharmacology, 2009
- Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ ChannelsMolecular Pharmacology, 2009
- KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromesNeurology, 2008
- Nervous system KV7 disorders: breakdown of a subthreshold brakeThe Journal of Physiology, 2008
- Retigabine: Has the Orphan Found a Home?Epilepsy Currents, 2007
- Retigabine: Bending Potassium Channels to Our WillEpilepsy Currents, 2005
- The Role of bcl‐2 Family of Genes During KindlingEpilepsia, 2005
- Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady‐state in healthy subjectsBritish Journal of Clinical Pharmacology, 2003
- AWD 140–190: a new anticonvulsant with a very good margin of safetyEpilepsy Research, 1997